Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
    • ACR Convergence 2022
    • Kidney Week 2022
    • AIDS 2022
COVID-19 Curbside Consults

The beneficial and pathogenic roles of complement in COVID-19

Alfred H.J. Kim, MD, PhD, Xiaobo Wu, MD and John P. Atkinson, MD
Cleveland Clinic Journal of Medicine October 2020, DOI: https://doi.org/10.3949/ccjm.87a.ccc065
Alfred H.J. Kim
Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Xiaobo Wu
Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
John P. Atkinson
Division of Rheumatology, Department of Medicine, Washington University School of Medicine, St. Louis, MO
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: [email protected]
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

ABSTRACT

We briefly summarize the complement system and its functions in immunity and disease. We present data supporting the requirement of complement to resolve COVID-19, and discuss how complement overactivation later in severe disease could drive multiorgan damage characteristic of fatal COVID-19.

INTRODUCTION

The coronavirus disease 2019 (COVID-19) pandemic has created a healthcare crisis unmatched in our lifetime. Caused by severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2), more than 28 million cases have been reported worldwide, including more than 7.6 million in the United States (https://coronavirus.jhu.edu/map.html). This disease has resulted in at least 1 million deaths globally, and more than 213,000 of these in the United States.

COVID-19 has a widely varied presentation (Table 1), being asymptomatic in 20% to 40% of cases, a common cold or influenza syndrome in 30% to 70%, or a severe life-threatening disease in less than 10%. Severe disease is characterized by respiratory failure, a hyperinflammatory internal milieu, and multiorgan thrombotic complications.

View this table:
  • View inline
  • View popup
TABLE 1

Clinical classification of COVID-19 infection, and the role of complement activation

The complement system has recently gained interest as a contributing player to certain pathogenic features of severe COVID-19 infection, particularly relative to thrombotic microangiopathy (TMA). Autopsy reports have also identified complement-mediated pathologic features consistent with manifestations of TMA such as endothelial cell abnormalities and complement fragment deposition in the lungs, skin, and kidney.1,2 In addition, recent transcriptional and genetic loci studies have provided further evidence for the involvement of the complement system in COVID-19. Indeed, therapies targeting complement components demonstrate preliminary success in treating severe COVID-19.3–5 But what has been somewhat ignored is the antiviral contribution of the complement system in a response to COVID-19, particularly early in the infection.

Herein, we briefly summarize the complement system and its functions in immunity and disease, presenting data supporting both the requirement of complement to resolve COVID-19, and how complement overactivation later in severe disease could drive multiorgan damage characteristic of fatal COVID-19. For the sake of brevity, we have primarily referenced a limited number of reviews and original reports with a focus on the complement system.2–13

THE COMPLEMENT SYSTEM IN IMMUNITY AND DISEASE

The complement system is a proteolytic cascade initiated by three pathways (classical, alternative, and lectin), each uniquely triggered to generate a potent, highly regulated, innate immune response and to set the stage for a prompt and decisive adaptive immune response: 1) membrane perturbation featuring C4b-and C3b-mediated opsonization/phagocytosis, as well as a lytic process mediated by the membrane attack complex (MAC, C5b-9), and 2) generation of a pro-inflammatory state largely mediated via the anaphylatoxins C3a and C5a. Using these same two general mechanisms, the complement system also facilitates the clearance of apoptotic material and cellular debris. Further, intracellular complement activation enables cells to modulate metabolic pathways and thereby regulate immune responsiveness.6

In systemic lupus erythematosus (SLE) and related autoimmune diseases, immune complexes generated by autoantibodies drive type II and III hypersensitivity reactions that leverage primarily the classical pathway activation to initiate destructive inflammatory responses.2,7 Interestingly, the failure to clear apoptotic debris, such as in complete classical pathway component C1q, C4, or C2 deficiency, is strongly predisposing to SLE.8 In age-related macular degeneration and atypical hemolytic uremic syndrome, loss of function (commonly haploinsufficiency) of complement regulatory proteins or gain of function in complement activating components promotes excessive alternative pathway engagement, leading to retinal damage in age-related macular degeneration and microthrombi featuring endothelial injury in atypical hemolytic uremic syndrome.2,7

EARLY CONTROL OF SARS-COV-2 LIKELY REQUIRES COMPLEMENT ACTIVATION

In the early phase of the innate immune response in COVID-19, a robust antiviral response to SARS-CoV-2 occurs in which the complement system plays an important role. Natural and cross-reacting antibodies and lectins trigger complement activation to destroy complement-coated virus and block viral entry. Mice infected with the related SARS-CoV virus generate numerous C3 activation products (C3a, C3b, iC3b, C3c, C3d) in the lung within a day. 9 Infection of cells by SARS-CoV-2 may promote C3 activation, as suggested in a preprint publication demonstrating that the N protein of SARS-CoV-2 activated the mannan-binding lectin-associated serine protease (MASP-2).14 In another report utilizing an in vitro system, spike proteins 1 and 2 led to activation primarily of the alternative pathway on human cells.13 These types of innate immune responses coupled with a rapid adaptive response lead to either no clinical signs of infection or a common cold-like or influenza-like syndrome.

Viruses, as might be expected, have developed evasion tactics to limit complement activation.10 For example, poxviruses express a protein that is structurally and functionally similar to human complement regulatory proteins. Other pathogens “hijack” our own regulators to protect themselves. Flaviviruses produce proteins that down-regulate the complement system’s activating capabilities. It remains unknown whether coronaviruses also possess antiviral activity.

INADEQUATE COMPLEMENT ACTIVATION CHARACTERIZES LATE COVID-19

Inadequate control of SARS-CoV-2 replication early in infection will lead to a heavier viral load, and an exuberant immune response will naturally follow, including complement activation. A robust proinflammatory cytokine (interleukin 6, interleukin 8) response has been observed in severe infections (often associated with a so-called cytokine release or cytokine storm syndrome). This result could be secondary in part to the viral damage to infected tissues (even though viral replication is halted), but an exuberant immune response to the accumulating debris occurs.3,4,9

Further, data implicating a prominent role for the complement system in severe COVID-19 came from early clinicopathologic studies. C5b-9, C4d, and MASP-2 deposition was noted in affected tissues, including the skin in those with reticuliform and purpuric lesions and the lung microvasculature in patients who died due to respiratory failure.1 C5b-9 deposition was also observed in the microvasculature in unaffected deltoid skin in 21 out of 23 hospitalized COVID-19 patients, which colocalized with the SARS-CoV-2 spike protein and ACE2 in the endothelial cells.15 While COVID-19 lung pathology is distinct from typical acute respiratory distress syndrome, complement activation within the lung has commonly been observed in acute respiratory distress syndrome, suggesting a possible common etiology.12 Complement activation fragments have also been observed to be elevated in serum of patients with severe COVID-19.2 Additionally, histopathologic features with similarities to other complement-mediated diseases indicate that complement deposition is a pathologic actor in severe COVID-19. Endothelial cell abnormalities such as cellular swelling with foamy degeneration in the setting of TMA have been observed in numerous organs, consistent with C5b-9–mediated injury and a hypercoagulable state. These data are consistent with the murine model of SARS-CoV, in which C3-deficient mice experienced less lung inflammation and injury.9

One mechanism by which complement may be overactivated in severe COVID-19 lies in the interplay between neutrophils and complement. Activated neutrophils generate extracellular chromatin-rich structures called neutrophil “traps,” which bind pathogenic material. Neutrophil traps promote alternative pathway activation as they contain C3, factor B, and properdin. Exuberant neutrophil activation and formation of neutrophil traps have been noted in patients with severe COVID-19.2

CONCLUSION

It is clear that complement activation occurs in COVID-19 and likely serves different roles depending on the time course of the infection (Table 1). Early clinical management of COVID-19 needs not only to support innate immunity including complement activation against the virus, but also to curtail subsequent potential damage to the tissues or organs in the severe syndrome (assuming viral replication has been largely stopped). Early on, complement is required to assist antiviral responses, such as clearing of complement-coated virions. Later, in the subset of patients with severe COVID-19 disease (too much virus or tissue damage), complement drives several of the observed pathogenic features. This has substantial implications in the use of complement therapeutics.

Scenarios in which timing of complement activation needs to be considered include the transfusion of convalescent plasma, which will form immune complexes with the intact virus (a good effect) but also with viral remnants and damaged tissues, potentially exacerbating the situation. Similarly, the use of steroids (or other immune-inflammatory suppressors) could inhibit the immune response to COVID-19. Here again, the timing of the administration of these immunosuppressive medications could be critical, as is knowledge relative to the viral load and replicating capability.

Thus, the timing of administration may lead to poor or improved outcomes. On one hand, complement inhibition in early disease may lead to worse clinical outcomes or poor protective responses, while in late disease, complement inhibition may improve outcomes. Indeed, preliminary reports of complement inhibition in severe COVID-19 have been encouraging. For example, a novel inhibitor to C3, AMY-101, which prevents C3 cleavage to C3a and C3b, has anecdotal success in severe COVID-19. This led to an active phase II trial in COVID-19 patients with respiratory distress.3,5 Furthermore, monoclonal antibodies targeting C5 activation (eculizumab, ravulizumab) have also demonstrated efficacy in COVID-19, with several active phase III clinical trials currently recruiting.4,5 Additional answers will emerge as these and other clinical trials report their results, providing an improved understanding of how to best manipulate the complement system in COVID-19.

Footnotes

  • Dr. Kim has disclosed consulting for Alexion Pharmaceuticals. Dr. Wu and Dr. Aktinson have nothing to disclose.

  • The statements and opinions expressed in COVID-19 Curbside Consults are based on experience and the available literature as of the date posted. While we try to regularly update this content, any offered recommendations cannot be substituted for the clinical judgment of clinicians caring for individual patients.

  • Copyright © 2020 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Magro C,
    2. Mulvey JJ,
    3. Berlin D, et al
    . Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: a report of five cases. Transl Res 2020; 220:1–13. doi:10.1016/j.trsl.2020.04.007
    OpenUrlCrossRefPubMed
  2. ↵
    1. Java A,
    2. Apicelli AJ,
    3. Liszewski MK, et al
    . The complement system in COVID-19: friend and foe? JCI Insight 2020; 5(15):e140711. doi:10.1172/jci.insight.140711
    OpenUrlCrossRef
  3. ↵
    1. Mastaglio S,
    2. Ruggeri A,
    3. Risitano AM, et al
    . The first case of COVID-19 treated with the complement C3 inhibitor AMY-101. Clin Immunol 2020; 215:108450. doi:10.1016/j.clim.2020.108450
    OpenUrlCrossRef
  4. ↵
    1. Kulasekararaj AG,
    2. Lazana I,
    3. Large J, et al
    . Terminal complement inhibition dampens the inflammation during COVID-19. Br J Haematol 2020; 190(3):e141–e143. doi:10.1111/bjh.16916
    OpenUrlCrossRef
  5. ↵
    1. Mastellos DC,
    2. Pires da Silva BGP,
    3. Fonseca BAL, et al
    . Complement C3 vs C5 inhibition in severe COVID-19: early clinical findings reveal differential biological efficacy. Clin Immunol 2020; 220:108598. doi:10.1016/j.clim.2020.108598
    OpenUrlCrossRef
  6. ↵
    1. Liszewski MK,
    2. Elvington M,
    3. Kulkarni HS,
    4. Atkinson JP
    . Complement’s hidden arsenal: new insights and novel functions inside the cell. Mol Immunol 2017; 84:2–9. doi:10.1016/j.molimm.2017.01.004
    OpenUrlCrossRef
  7. ↵
    1. Liszewski MK,
    2. Java A,
    3. Schramm EC,
    4. Atkinson JP
    . Complement dysregulation and disease: insights from contemporary genetics. Annu Rev Pathol 2017; 12:25–52. doi:10.1146/annurev-pathol-012615-044145
    OpenUrlCrossRefPubMed
  8. ↵
    1. Macedo AC,
    2. Isaac L
    . Systemic lupus erythematosus and deficiencies of early components of the complement classical pathway. Front Immunol 2016; 7:55. doi:10.3389/fimmu.2016.00055
    OpenUrlCrossRefPubMed
  9. ↵
    1. Gralinski LE,
    2. Sheahan TP,
    3. Morrison TE, et al
    . Complement activation contributes to severe acute respiratory syndrome coronavirus pathogenesis. mBio 2018; 9(5): e01753-18. doi:10.1128/mBio.01753-18
    OpenUrlCrossRef
  10. ↵
    1. Stoermer KA,
    2. Morrison TE
    . Complement and viral pathogenesis. Virology 2011; 411(2):362–373. doi: 10.1016/j.virol.2010.12.045
    OpenUrlCrossRefPubMed
    1. Vabret N,
    2. Britton GJ,
    3. Gruber C, et al
    . Immunology of COVID-19: current state of the science. Immunity 2020; 52(6):910–941. doi:10.1016/j.immuni.2020.05.002
    OpenUrlCrossRefPubMed
  11. ↵
    1. Robbins RA,
    2. Russ WD,
    3. Rasmussen JK,
    4. Clayton MM
    . Activation of the complement system in the adult respiratory distress syndrome. Am Rev Respir Dis 1987; 135(3):651–658. doi: 10.1164/arrd.1987.135.3.651
    OpenUrlCrossRefPubMed
  12. ↵
    1. Yu J,
    2. Yuan X,
    3. Chen H,
    4. Chaturvedi S,
    5. Braunstein EM,
    6. Brodsky RA
    . Direct activation of the alternative complement pathway by SARS-CoV-2 spike proteins is blocked by factor D inhibition. Blood 2020; blood.2020008248. doi:10.1182/blood.2020008248.
    OpenUrlCrossRef
  13. ↵
    1. Gao T,
    2. Hu M,
    3. Zhang X, et al
    . Highly pathogenic coronavirus N protein aggravates lung injury by MASP-2-mediated complement overactivation. medRxiv 2020. doi:https://doi.org/10.1101/2020.03.29.20041962.
  14. ↵
    1. Magro C,
    2. Mulvey JJ,
    3. Laurence J, et al
    . Docked SARS-CoV-2 Proteins within the Cutaneous and Subcutaneous Microvasculature and their Role in the Pathogenesis of Severe COVID-19. Human Path 2020; Online 12 October 2020. doi:10.1016/j.humpath.2020.10.002
    OpenUrlCrossRef
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 92 (5)
Cleveland Clinic Journal of Medicine
Vol. 92, Issue 5
1 May 2025
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
The beneficial and pathogenic roles of complement in COVID-19
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Citation Tools
The beneficial and pathogenic roles of complement in COVID-19
Alfred H.J. Kim, Xiaobo Wu, John P. Atkinson
Cleveland Clinic Journal of Medicine Oct 2020, DOI: 10.3949/ccjm.87a.ccc065

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
The beneficial and pathogenic roles of complement in COVID-19
Alfred H.J. Kim, Xiaobo Wu, John P. Atkinson
Cleveland Clinic Journal of Medicine Oct 2020, DOI: 10.3949/ccjm.87a.ccc065
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget
  • Facebook Like
  • Linkedin Share Button

Jump to section

  • Article
    • ABSTRACT
    • INTRODUCTION
    • THE COMPLEMENT SYSTEM IN IMMUNITY AND DISEASE
    • EARLY CONTROL OF SARS-COV-2 LIKELY REQUIRES COMPLEMENT ACTIVATION
    • INADEQUATE COMPLEMENT ACTIVATION CHARACTERIZES LATE COVID-19
    • CONCLUSION
    • Footnotes
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Update to COVID-19 serologic testing : FAQs and caveats
  • Update to post-acute sequelae of SARS-CoV-2 infection: Caring for the 'long-haulers'
  • COVID-19 in older adults
Show more COVID-19 Curbside Consults

Similar Articles

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2025 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire